(88 days)
Not Found
No
The document explicitly states "Mentions AI, DNN, or ML: Not Found" and the device description focuses on standard medical device functionalities like defibrillation, monitoring, and pacing without mentioning any AI/ML components.
Yes.
The device performs defibrillation and pacing, which are therapeutic interventions aimed at treating specific cardiac conditions.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states "ECG monitoring is used for identifying and diagnosing cardiac rhythms and dysrhythmias and calculating heart rate." This clearly indicates a diagnostic function.
No
The device description clearly states it is a "complete acute cardiac response system - battery or auxiliary powered defibrillator (manual and AED), monitor, pacemaker, 3 lead ECG, interpretive 12 lead ECG and pulse oximeter," indicating it includes significant hardware components beyond just software.
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- Intended Use: The intended uses described (defibrillation, pacing, ECG monitoring, pulse oximetry) are all direct physiological interventions or measurements performed on the patient's body. IVDs are used to examine specimens (like blood, urine, tissue) outside the body to provide information about a patient's health.
- Device Description: The description details a device that interacts directly with the patient (defibrillator, monitor, pacemaker).
- No mention of specimen analysis: There is no indication that this device analyzes any biological specimens.
Therefore, the LIFEPAK 12 defibrillator/monitor series falls under the category of a medical device used for direct patient care and monitoring, not an IVD.
N/A
Intended Use / Indications for Use
Defibrillation is a means of terminating ventricular fibrillation and ventricular tachycardia. The biphasic waveform used in this device has only been clinically tested on adults; it has not been tested on pediatric patients. The AED mode is for use on patients in cardiopulmonary arrest. Pacing is used to treat symptomatic bradycardia and asystole. ECG monitoring is used for identifying and diagnosing cardiac rhythms and dysrhythmias and calculating heart rate. Pulse oximetry is used to check the saturation of in the arterial blood of patients who are at risk of developing hypoxemia.
Product codes (comma separated list FDA assigned to the subject device)
74 MKJ, DRO, LOS, LDD, and DQA
Device Description
The LIFEPAK 12 defibrillator/monitor series is a complete acute cardiac response system - battery or auxiliary powered defibrillator (manual and AED), monitor, pacemaker, 3 lead ECG, interpretive 12 lead ECG and pulse oximeter. Data can be transmitted by landline or cell phone to computer, fax, printer, or ECG storage system
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
The biphasic waveform used in this device has only been clinically tested on adults; it has not been tested on pediatric patients. Inc device has not been evaluated for AF or for dicect cardiac defibrilate
The AED mode is not intended for use on children less than eight years of age, per AHA guidelines.
Intended User / Care Setting
The users will be Advanced Life Support and Basic Life Support providers in a variety of hospital and prehospital settings. Emergency Medical Services users will include Paramedics and Emergency Medical Technicians trained and authorized to respond to medical emergencies. This device will be used in the prehospital setting and in the hospital, in critical areas (emergency departments, critical care, operating rooms, etc.) and on general duty floors (e.g. medical/surgical.) It will also be used for in and out of hospital transport (air and ground ambulance, in hospital transport, etc.)
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The efficacy of the Physio-Control BTE waveform was demonstrated in a multi site clinical study. The results of that study are reported in the 510(k).
Information is also provided in the 510(k) regarding compliance to applicable sections of the following voluntary industry standards:
- ANSI/AAMI DF2 1989, Cardiac Defibrillator Devices Standard .
- ANSI/AAMI DF39 1993, Automatic External Defibrillator Standard ♥
This information demonstrates that the LIFEPAK 12 is substantially equivalent to the predicate devices with respect to safety, effectiveness, and performance.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.5310 Automated external defibrillator system.
(a)
Identification. An automated external defibrillator (AED) system consists of an AED and those accessories necessary for the AED to detect and interpret an electrocardiogram and deliver an electrical shock (e.g., battery, pad electrode, adapter, and hardware key for pediatric use). An AED system analyzes the patient's electrocardiogram, interprets the cardiac rhythm, and automatically delivers an electrical shock (fully automated AED), or advises the user to deliver the shock (semi-automated or shock advisory AED) to treat ventricular fibrillation or pulseless ventricular tachycardia.(b)
Classification. Class III (premarket approval)(c)
Date PMA or notice of completion of PDP is required. A PMA will be required to be submitted to the Food and Drug Administration by April 29, 2015, for any AED that was in commercial distribution before May 28, 1976, or that has, by April 29, 2015, been found to be substantially equivalent to any AED that was in commercial distribution before May 28, 1976. A PMA will be required to be submitted to the Food and Drug Administration by April 29, 2015, for any AED accessory described in paragraph (a) that was in commercial distribution before May 28, 1976, or that has, by April 29, 2015, been found to be substantially equivalent to any AED accessory described in paragraph (a) that was in commercial distribution before May 28, 1976. Any other AED and AED accessory described in paragraph (a), shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
0
3 1999 859
510(k) Summary
Submitter's Name and Address: Medtronic Physio-Control Corp. 11811 Willows Road Northeast P.O. Box 97006 Redmond, WA 98073
Mike Willingham, Tel. (425) 867-4329 Contact Person:
August 5, 1999 Date Summary Prepared:
Device:
Physio-Control Corporation Biphasic LIFEPAK® 12 defibrillator / monitor / pacemaker system
Classification:
Low-Energy DC - Defibrillators (including Paddles): Class II (21 CFR 870.5300)
Cardiac Monitors (including cardiotachometers and Rate Alarms): Class II (21 CFR 870.2300)
External Transcutaneous Cardiac Pacemakers (noninvasive): Class III (870.5550)
Oximeter: Class II (21 CFR 870.2700)
Automated External Defibrillator and Interpretive 12 lead ECG: Class III
Substantial Equivalence:
The intended use and function of the Biphasic LIFEPAK 12 system are substantially equivalent to those of the:
Physio-Control LIFEPAK 12 defibrillator/pacemaker, 510(k) no. K973486.
Physio-Control LIFEPAK 500 automated external defibrillator, 510(k) no. K983393
Heartstream Forerunner defibrillator, 510(k) no. K955628.
Mine Safety defibrillator, Preamendment.
1
Description:
The LIFEPAK 12 defibrillator/monitor series is a complete acute cardiac response system - battery or auxiliary powered defibrillator (manual and AED), monitor, pacemaker, 3 lead ECG, interpretive 12 lead ECG and pulse oximeter. Data can be transmitted by landline or cell phone to computer, fax, printer, or ECG storage system
The users will be Advanced Life Support and Basic Life Support providers in a variety of hospital and prehospital settings. Emergency Medical Services users will include Paramedics and Emergency Medical Technicians trained and authorized to respond to medical emergencies. This device will be used in the prehospital setting and in the hospital, in critical areas (emergency departments, critical care, operating rooms, etc.) and on general duty floors (e.g. medical/surgical.) It will also be used for in and out of hospital transport (air and ground ambulance, in hospital transport, etc.)
Indications for Use:
Defibrillation is a means of terminating ventricular fibrillation and ventricular tachycardia. The biphasic waveform used in this device has only been clinically tested on adults; it has not been tested on pediatric patients. The AED mode is for use on patients in cardiopulmonary arrest. Pacing is used to treat symptomatic bradycardia and asystole. ECG monitoring is used for identifying and diagnosing cardiac rhythms and dysrhythmias and calculating heart rate. Pulse oximetry is used to check the saturation of in the arterial blood of patients who are at risk of developing hypoxemia.
Technological characteristics of new and predicate devices:
The new Biphasic LIFEPAK 12 defibrillator uses a Biphasic Truncated Exponential (BTE) waveform. The predicate LIFEPAK 12 defibrillator uses a monophasic damped sine waveform; the predicate LIFEPAK 500 and Heartstream Forerunner defibrillators use a BTE waveform: the Mine Safety defibrillator uses a biphasic exponential waveform. The pacing, 12 lead monitor, 3 lead monitor, and Pulse Oximetry features are the same as those in the original LIFEPAK 12 defibrillator.
2
Summary of Performance Information:
The efficacy of the Physio-Control BTE waveform was demonstrated in a multi site clinical study. The results of that study are reported in the 510(k).
Information is also provided in the 510(k) regarding compliance to applicable sections of the following voluntary industry standards:
- ANSI/AAMI DF2 1989, Cardiac Defibrillator Devices Standard .
- ANSI/AAMI DF39 1993, Automatic External Defibrillator Standard ♥
This information demonstrates that the LIFEPAK 12 is substantially equivalent to the predicate devices with respect to safety, effectiveness, and performance.
3
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
SEP 3 1999
Mr. Michael D. Willingham Vice President, Quality and Regulatory Affairs Medtronic Physio-Control Corp. 11811 Willows Road Northeast Post Office Box 97006 Redmond, WA 98073-9706
Re: K991910 LIFEPAK® 12 Biphasic Defibrillator/Monitor System Regulatory Class: III (three) Product Code: 74 MKJ, DRO, LOS, LDD, and DQA Dated: June 3, 1999 Received: June 7, 1999
Dear Mr. Willingham:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments. You may, therefore, market the device, subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act (Act). The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, and labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Requlation (QS) for Medical Devices: General requlation (21 CFR Part 820) and that, through periodic QS inspections, FDA will verify such assumptions. Failure to comply with the GMP requlation may result in requlatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under section 531 through 542 of the Act for
4
Page 2 - Mr. Michael D. Willingham
devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.
On August 16, 1993 the Final Rule for Device Tracking was published in the Federal Register, pages 43442-43455 (copy enclosed). Be advised that under Section 519(e) of the Act as amended by the Safe Medical Devices Act of 1990, FDA has identified the above device as a device which requires tracking. Because the device is subject to tracking, you are required to adopt a method of tracking that follows the devices through the distribution chain and then identifies and follows the patients who receive them. The specific requirements of the regulation are found in 21 CFR 821 as described in the August 16, 1993 Federal Register beginning on page 43447.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please not the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act, may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Thomas J. Callahlan
Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosures
5
LIFEPAK 12 biphasic defibrillator/monitor series - Indications for Use
Defibrillator
Defibrillation therapy is used as a means of terminating ventricular fibrillation and ventricular tachycardia. The biphasic waveform used in this device has only been clinically tested on adults; it has not been tested on pediatric patients. Inc device has not been evaluated for AF or for dicect cardiac defibrilate
Automated External Defibrillator feature
The AED mode is to be used only on patients in cardiopulmonary arrest. The patient must be unconscious, pulseless, and not breathing spontaneously before using the defibrillator to analyze the patient's ECG rhythm. The AED mode is not intended for use on children less than eight years of age, per AHA guidelines.
Noninvasive Pacemaker
Noninvasive pacing is used as a means of treating symptomatic bradycardia and asvstole.
Electrocardiograph
3-Lead (3 wire) and 6-Lead (4 wire) ECG Monitoring:
The 3 and 4 wire ECG allows for identification or interpretation of cardiac rhythms or dysrhythmias and calculation of heart rate.
12-lead electrocardiogram (ECG)
The 12-lead electrocardiogram (ECG) is used to identify, diagnose, and treat patients with cardiac disorders and is useful in the early detection and prompt treatment of patients with acute myocardial infarction.
Pulse Oximetery
A pulse oximeter is a noninvasive device that checks the saturation of oxygen in arterial blood (SpO2). It is used for monitoring patients who are at risk of developing hypoxemia.
c. Cary
08/26/99
✓ PRESCRIPTION USE
fo Hlextrada